TAMPA, FL - February 27, 2026 - PRESSADVANTAGE - Lauren A. Leikam, PLLC, a Florida healthcare license defense firm, has ...

Completed enrollment of Cohort C in the Phase 1 ALLOHA™ trial; patients to be treated with commercial-ready manufacturing processReceived FDA ...

The trial compares two injections. Elritercept (also known as TAK-226) is Takeda’s experimental drug designed to boost red blood cell production and reduce dependence on transfusions. Epoetin alfa is ...

Regulatory changes to the nursing home industry for this year may seem small individually, but together, they reflect broader initiatives sought by the ...

CareDx CDNA recently announced clinical validation data supporting AlloHeme, its next-generation, blood-based monitoring test designed to predict relapses in patients with acute myeloid leukemia (AML) ...

Myelodysplastic syndromes (MDS) are heterogeneous myeloid clonal disorders derived from hematopoietic stem cells. The incidence of MDS (1.51/100,000 in China, 4-5/100,000 in Europe and America) is ...

A novel blood based surveillance test using artificial intelligence and next-generation sequencing identified relapse a median of 41 days before clinical detection in patients with AML or MDS ...

Robust SENTI-202 clinical data presented at ASH 2025 demonstrated deep, MRD-negative, durable complete remissions and a favorable safety ...

Abstract: As cyclic codes and maximum distance separable (MDS) codes, cyclic MDS codes have very nice structures and properties, which have been intensively investigated in literature due to their ...